The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) closed the day trading at $7.19 down -9.10% from the previous closing price of $7.91. In other words, the price has decreased by -$9.10 from its previous closing price. On the day, 0.74 million shares were traded. KPTI stock price reached its highest trading level at $8.0669 during the session, while it also had its lowest trading level at $7.15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 01 ’25 when Abate Kristin sold 362 shares for $6.30 per share. The transaction valued at 2,279 led to the insider holds 10,046 shares of the business.
Paulson Richard A. sold 1,257 shares of KPTI for $8,083 on Sep 15 ’25. The President and CEO now owns 84,046 shares after completing the transaction at $6.43 per share. On Sep 15 ’25, another insider, Mano Michael, who serves as the SVP, General Counsel&Secretary of the company, sold 234 shares for $6.43 each. As a result, the insider received 1,505 and left with 21,425 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KPTI now has a Market Capitalization of 131650944 and an Enterprise Value of 346640800. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.92. Its current Enterprise Value per Revenue stands at 2.432 whereas that against EBITDA is -3.34.
Stock Price History:
The Beta on a monthly basis for KPTI is 0.22, which has changed by -0.24450815 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, KPTI has reached a high of $10.80, while it has fallen to a 52-week low of $3.51. The 50-Day Moving Average of the stock is 11.69%, while the 200-Day Moving Average is calculated to be 29.13%.
Shares Statistics:
Over the past 3-months, KPTI traded about 215.61K shares per day on average, while over the past 10 days, KPTI traded about 498270 shares per day. A total of 18.31M shares are outstanding, with a floating share count of 17.18M. Insiders hold about 6.73% of the company’s shares, while institutions hold 16.81% stake in the company. Shares short for KPTI as of 1767139200 were 353885 with a Short Ratio of 1.64, compared to 1764288000 on 341393. Therefore, it implies a Short% of Shares Outstanding of 353885 and a Short% of Float of 2.22.
Earnings Estimates
The stock of Karyopharm Therapeutics Inc (KPTI) is currently in the spotlight, with 2.0 analysts actively rating and assessing its market standing.The consensus estimate for the next quarter is -$1.33, with high estimates of -$1.09 and low estimates of -$1.56.
Analysts are recommending an EPS of between -$11.46 and -$12.61 for the fiscal current year, implying an average EPS of -$12.03. EPS for the following year is -$4.93, with 2.0 analysts recommending between -$4.6 and -$5.25.
Revenue Estimates
6 analysts predict $35.84M in revenue. The current quarter. It ranges from a high estimate of $39.36M to a low estimate of $33.35M. As of. The current estimate, Karyopharm Therapeutics Inc’s year-ago sales were $30.54MFor the next quarter, 6 analysts are estimating revenue of $34.24M. There is a high estimate of $38.5M for the next quarter, whereas the lowest estimate is $32.5M.
A total of 6 analysts have provided revenue estimates for KPTI’s current fiscal year. The highest revenue estimate was $151.34M, while the lowest revenue estimate was $145.34M, resulting in an average revenue estimate of $147.83M. In the same quarter a year ago, actual revenue was $145.24MBased on 6 analysts’ estimates, the company’s revenue will be $146.91M in the next fiscal year. The high estimate is $162.22M and the low estimate is $131.4M.
